 |
|
Comparative Benefits of Clopidogrel and Aspirin in High-Risk Patient Populations
Lessons From the CAPRIE and CURE Studies
Jack Hirsh, CM, MD, FRCPC, FRACP, FRSC, DSc;
Deepak L. Bhatt, MD, FACC, FSCAI, FESC
Arch Intern Med. 2004;164:2106-2110.
Clopidogrel has been evaluated in clinical trials that included cardiovascular patients with different risk levels for a cardiovascular event. We reviewed the results of the Clopidogrel vs Aspirin in Patients at Risk of Ischemic Events (CAPRIE) and Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) trials, with special emphasis on comparing the outcomes in high-risk patients with those of the total populations in the trials. The results in the high-risk subgroups and total populations were compared by recording total event rates, absolute risk reduction, relative risk reduction, and number needed to treat. In the CAPRIE trial, the efficacy of clopidogrel was compared with acetylsalicylic acid (ASA) in the following subgroups: total population, previous coronary bypass surgery, history of more than1 ischemic event, multiple vascular beds involvement, diabetes, and hypercholesterolemia. In the CURE trial, the combination of clopidogrel and ASA was compared with ASA alone. The results in the CURE study were compared in patients who did and did not have a coronary intervention procedure, in patients with different levels of risk based on the Thrombolysis in Myocardial Infarction score and in patients with and without a history of a revascularization procedure. High-risk subgroups of patients participating in the CAPRIE and CURE studies were more responsive to the beneficial effects of clopidogrel compared with the study population as a whole. High-risk groups in the CAPRIE and CURE studies would be expected to derive enhanced benefit from treatment with clopidogrel over that achieved by ASA.
Author Affiliations: The Henderson Research Centre, Hamilton, Ontario (Dr Hirsh); and the Cleveland Clinic Foundation, Cleveland, Ohio (Dr Bhatt).
RELATED LETTERS
The (Variable) Definition of Benefit in the Case of Clopidogrel vs Aspirin
Donald B. Hansen
Arch Intern Med. 2005;165(11):1310.
EXTRACT
| FULL TEXT
The (Variable) Definition of Benefit in the Case of Clopidogrel vs Aspirin—Reply
Deepak L. Bhatt and Jack Hirsh
Arch Intern Med. 2005;165(11):1310-1311.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
The diabetic foot
Khanolkar et al.
QJM 2008;101:685-695.
ABSTRACT
| FULL TEXT
Review: Aspirin and Diabetes Mellitus: revisiting an old player
Manrique et al.
Therapeutic Advances in Cardiovascular Disease 2008;2:37-42.
ABSTRACT
Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)
Authors/Task Force Members et al.
Eur Heart J Suppl 2007;9:C3-C74.
FULL TEXT
Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)
Authors/Task Force Members et al.
Eur Heart J 2007;28:88-136.
FULL TEXT
Bleeding and management of bleeding
Eikelboom and Hirsh
Eur Heart J Suppl 2006;8:G38-G45.
ABSTRACT
| FULL TEXT
The Role of Antiplatelet Therapy in Carotid Stenting for Ischemic Stroke Prevention
Chaturvedi and Yadav
Stroke 2006;37:1572-1577.
ABSTRACT
| FULL TEXT
Aspirin and clopidogrel resistance: an emerging clinical entity
Wang et al.
Eur Heart J 2006;27:647-654.
ABSTRACT
| FULL TEXT
What is the future of diabetic wound care?
Sweitzer et al.
The Diabetes Educator 2006;32:197-210.
ABSTRACT
| FULL TEXT
The (Variable) Definition of Benefit in the Case of Clopidogrel vs Aspirin
Hansen
Arch Intern Med 2005;165:1310-1310.
FULL TEXT
The (Variable) Definition of Benefit in the Case of Clopidogrel vs Aspirin--Reply
Bhatt and Hirsh
Arch Intern Med 2005;165:1310-1311.
FULL TEXT
|
